The role of vesicular transport proteins in synaptic transmission and neural degeneration

Annual Review of Neuroscience

Volumn 20, Issue , 1997, Pages 125-156

  Liu, Yongjian ^a   Edwards, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dense core vesicles; neurotransmitter transport; Parkinson's disease; synaptic vesicles; vesicular transport

Indexed keywords

ACETYLCHOLINE; COMPLEMENTARY DNA; NEUROTRANSMITTER;

ACETYLCHOLINE RELEASE; AMINO ACID SEQUENCE; HUMAN; MEMBRANE VESICLE; NERVE CELL DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SEQUENCE HOMOLOGY; SYNAPTIC TRANSMISSION; TRANSPORT KINETICS;

ANIMALS; CARRIER PROTEINS; NERVE DEGENERATION; SYNAPTIC TRANSMISSION; SYNAPTIC VESICLES;

EID: 0031044233     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.20.1.125     Document Type: Review

References (157)

1. Albores R, Neafsey EJ, Drucker G, Fields JZ, Collins MA. 1990. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc. Natl. Acad. Sci. USA 87:9368-72
2. Alfonso A, Grundahl K, Duerr JS, Han, H-P, Rand JB. 1993. The Caenorhabditis elegans unc-17 gene: a putative vesicular acetylcholine transporter. Science 261:617-19
3. Alfonso A, Grundahl K, McManus JR, Asbury JM, Rand JB. 1994. Alternative splicing leads to two cholinergic proteins in Caenorhabditis elegans. J. Mol. Biol. 241:627-30
4. Amara SG, Kuhar MJ. 1993. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16:73-93
5. 3H-acetylcholine by Torpedo electric organ synaptic vesicles. Biochemistry 21:3037-43
6. Anderson DC, King SC, Parsons SM. 1983. Pharmacological characterization of the acetylcholine transport system in purified Torpedo electric organ synaptic vesicles. Mol. Pharmacol. 24:48-54
7. Bahr BA, Clarkson ED, Rogers GA, Noremberg K, Parsons SM. 1992. A kinetic and allosteric model for the acetylcholine transporter-vesamicol receptor in synaptic vesicles. Biochemistry 31:5752-62
8. Bahr BA, Parsons SM. 1986a. Acetylcholine transport and drug inhibition kinetics in Torpedo synaptic vesicles. J. Neurochem. 46:1214-18
9. 3H]piperidino) cyclohexanol. Proc. Natl. Acad. Sci. USA 83:2267-70
10. Bahr BA, Parsons SM. 1992. Purification of the vesamicol receptor. Biochemistry 31:5763-69
11. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. 1994. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J. Neurosci. 14:5223-35
12. Bajjalieh SM, Peterson K, Linial M, Scheller RH. 1993. Brain contains two forms of synaptic vesicle protein 2. Proc. Natl. Acad. Sci. USA 90:2150-54
13. Bajjalieh SM, Peterson K, Shinghal R, Scheller RH. 1992. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257:1271-73
14. Bejanin S, Cervini R, Mallet J, Berrard S. 1994. A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine. J. Biol. Chem. 269:21944-47
15. Berse B, Blusztajn JK. 1995. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine tranporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J. Biol. Chem. 270:22101-4
16. Betz WJ, Bewick GS. 1992. Optical analysis of synaptic vesicle cycling at the frog neuromuscular junction. Science 255:200-3
17. Buck KJ, Amara SG. 1994. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 91:12584-88
18. Buckley K, Kelly RB. 1985. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J. Cell Biol. 100:1284-94
19. Burger PM, Hell J, Mehl E, Krasel C, Lottspeich F, Jahn R. 1991. GABA and glycine in synaptic vesicles: storage and transport characteristics. Neuron 7:287-93
20. Cameron PL, Sudhof TC, Jann R, de Camilli P. 1991. Colocalization of synaptophysin with transferrin receptors: implications for synaptic vesicle biogenesis. J. Cell Biol. 115:151-64
21. Carlson MD, Kish PE, Ueda T. 1989a. Characterization of the solubilized and reconstituted ATP-dependent vesicular glutamate uptake system. J. Biol. Chem. 264:7369-76
22. Carlson MD, Kish PE, Ueda T. 1989b. Glutamate uptake into synaptic vesicles: competitive inhibition by bromocriptine. J. Neurochem. 53:1889-94
23. Carlsson A. 1965. Drugs which block the storage of 5-hydroxytryptamine and related amines. Handb. Exp. Pharmacol. 19:529-92
24. Cerruti C, Walther DM, Kuhar MJ, Uhl GR. 1993. Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Brain Res. Mol. Brain Res. 18:181-86
25. Cervini R, Houhou L, Pradat P-F, Bejanin S, Mallet J, Berrard S. 1995. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 270:24654-57
26. Chaplin L, Cohen AH, Huettl P, Kennedy M, Njus D, Temerley S. 1985. Reserpic acid as an inhibitor of norepinephrine transport into chromaffin vesicle ghosts. J. Biol. Chem. 260:10981-85
27. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-34
28. Cohen G. 1990. Monamine oxidase and oxidative stress at dopaminergic synapses. J. Neural Transm. Suppl. 32:229-38
29. Cubells JF, Rayport S, Rajendran G, Sulzer D. 1994. Methamphetamine neurotoxicity involves vacuolation of endocy tic organells and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:2260-71
30. D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH. 1987. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327:324-26
31. Daniels AJ, Reinhard JF. 1988. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffine granules via the catcholamine transporter. J. Biol. Chem. 263:5034-36
32. Darchen F, Scherman D, Laduron PM, Henry JP. 1988. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol. Pharmacol. 33:672-77
33. Darchen F, Scherman D, Henry JP. 1989. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28:1692-97
34. Denton T, Howard BD. 1987. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49:622-30
35. Desnos C, Laran M, Scherman D. 1992. Regulation of the chromaffin granule catecholamine transporter in cultured bovine adrenal medullary cells-stimulus biosynthesis coupling. J. Neurochem. 59:2105-12
36. Desnos C, Raynaud B, Vidai S, Weber MJ, Scherman D. 1990. Induction of the vesicular monoamine transporter by elevated potassium concentration in cultures of rat sympathetic neurons. Dev. Brain Res. 52:161-66
37. Deutch AY, Elsworth JD, Goldstein M, Fuxe K, Redmond DE, et al. 1986. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 68:51-56
38. Dexter DT, Carter CJ, Wells FR, Javoy-Agid Y, Lees A, et al. 1989a. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1830-36
39. Dexter DT, Jenner P, Schapira AHV, Marsden CD. 1992. Alterations in levels of iron, ferritin and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann. Neurol. 32:594-100
40. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, et al. 1989b. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1830-36
41. Eldridge R, Rocca WA. 1992. The genetic basis of common diseases. In The Genetic Basis of Common Diseases, ed. RA King, JI Rotter, AG Motulsky, 20:775-91. Oxford Monogr. Med. Genet. New York: Oxford Univ. Press
42. Erickson JD, Eiden LE. 1993. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61:2314-17
43. Erickson JD, Eiden LE, Hoffman BJ. 1992. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 89:10993-97
44. Erickson JD, Varoqui H, Schafer MD, Modi W, Diebler MF, et al. 1994. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem. 269:21929-32
45. Fahn S, Cohen G. 1992. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:804-12
46. Feany MB, Lee S, Edwards RH, Buckley KM. 1992. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell 70:861-67
47. Feany MB, Yee AG, Delvy ML, Buckley KM. 1993. The synaptic vesicle proteins SV2, synaptolagmin and synaptophysin are sorted to separate cellular compartments in CHO fibroblasts. J. Cell Biol. 123:575-84
48. Fisher JF, Cho AK. 1979. Chemical release of DA from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:203-9
49. Floor E, Leventhal PS, Wang Y, Meng L, Chen W. 1995. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J. Neurochem. 64:689-99
50. Forgac M. 1989. Structure and function of vacuolar class of ATP-driven proton pumps. Physiol. Rev. 69:765-96
51. Frize ED. 1954. Mental depression in hypertensive patients treated for long periods with high doses of reserpine. N. Engl. J. Med. 251:1006-8
52. German DC, Manaye KF, Sonsalla PK, Brooks BA. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. NY Acad. Sci. 648:42-62
53. Gilmor ML, Nash NR, Roghani A, Edwards RH, Yi H, et al. 1996. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. Submitted
54. Gingrich JA, Andersen PH, Tiberi M, El Mestikawy S, Jorgensen PN, et al. 1992. Identification, characterization and molecular cloning of a novel transporter-like protein localized to the central nervous system. FEBS Lett. 312:115-22
55. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. 1991. Correlation between the neostriatal content of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257:691-97
56. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. 1994. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: systemic administration. J. Pharmacol. Exp. Ther. 270:1000-7
57. Hartinger J, Jahn R. 1993. An anion binding site that regulates the glutamate transporter of synaptic vesicles. J. Biol. Chem. 268:23122-27
58. Heeringa MJ, Abercrombie ED. 1995. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J. Neurochem. 65:192-200
59. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-69
60. Hell JW, Edelmann L, Hartinger J, Jahn R. 1991. Functional reconstitution of the gamma-aminobutyric acid transporter from synaptic vesicles using artificial ion gradients. Biochemistry 30:11795-800
61. Hell JW, Maycox PR, Jahn R. 1990. Energy dependence and functional reconstitution of the gamma-aminobutyric acid carrier from synaptic vesicles. J. Biol. Chem. 265:2111-17
62. Hicks BW, Rogers GA, Parsons SM. 1991. Purification and characterization of a nonvesicular vesamicol-binding protein from electric organ and demonstration of a related protein in mammalian brain. J. Neurochem. 57:509-19
63. Hirsch E, Graybiel AM, Agid YA. 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-48
64. Howell M, Shirvan A, Stern-Bach Y, Steiner-Mordoch S, Strasser JE, et al. 1994. Cloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules. FEBS Lett. 338:16-22
65. Isambert MF, Gasnier B, Botton D, Henry JP. 1992. Characterization and purification of the monoamine transporter of bovine chromaffin granules. Biochemistry 31:1980-86
66. Javitch J, D'Amato R, Nye J, Javitch J. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82:2173-77
67. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32:82-87 (Suppl.)
68. Johannessen JN, Chiueh CC, Burns RS, Markey SP. 1985. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36:219-24
69. Johnson RG. 1988. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68:232-307
70. Jossan SS, Sakurai E, Oreland L. 1989. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol. Toxicol. 64:314-18
71. Kalivas PW, Duffy P. 1993. Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J. Neurosci. 13:276-84
72. Kaneko M, Yamaguchi A, Sawai T. 1985. Energetics of tetracycline efflux system encoded by Tn10 in Escherichia coli. FEBS Lett. 193:194-98
73. Kanner BI. 1994. Sodium-coupled neurotransmitter transport: structure, function and regulation. J. Exp. Biol. 196:237-49
74. Kanner BI, Schuldiner S. 1987. Mechanisms of storage and transport of neurotransmitters. CRC Crit. Rev. Biochem. 22:1-38
75. Kish PE, Fischer-Bovenkerk C, Ueda T. 1989. Active transport of gamma-aminobutyric acid and glycine into synaptic vesicles. Proc. Natl. Acad. Sci. USA 86:3877-81
76. 3H-Vesamicol binding in human brain cholinergic deficiency disorders. Neuroscience Lett. 117:347-52
77. +: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann. Neurol. 32:109-11
78. +-linked dopamine transport in chromaffin granule ghosts. Biochemistry 20:6625-29
79. Krejci E, Gasnier B, Botton D, Isambert MF, Sagne C, et al. 1993. Expression and regulation of the bovine vesicular monoamine transporter gene. FEBS Lett. 335:27-32
80. Landry D, Sullivan S, Nicolaides M, Redhead C, Edelman A, et al. 1993. Molecular cloning and characterization of p64, a chloride channel protein from kidney microsomes. J. Biol. Chem. 268:14948-55
81. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219:979-80
82. Langston JW, Irwin I, Langston EG, Forno LS. 1984. Pargyline prevents MPTP-induced parkinsonism in primates. Science 225:1480-82
83. Lesch KP, Gross J, Wolozin BL, Franzek E, Bengel D, et al. 1994. Direct sequencing of the reserpine-sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic depressive illness. Psychiatr. Genet. 4:153-60
84. + toxicity encodes a vesicular amine transporter. Cell 70:539-51
85. +. Proc. Natl. Acad. Sci. USA 89:9074-78
86. Liu Y, Schweitzer ES, Nirenberg MJ, Pickel VM, Evans CJ, Edwards RH. 1994. Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells. J. Cell Biol. 127:1419-33
87. Maron R, Stern Y, Kanner BI, Schuldiner S. 1983. Functional asymmetry of the amine transporter from chromaffin granules. J. Biol. Chem. 258:11476-81
88. Maycox PR, Deckwerth T, Hell JW, Jahn R. 1988. Glutamate uptake by brain synaptic vesicles. Energy dependence of transport and functional reconstitution in proteoliposomes. J. Biol. Chem. 263:15423-28
89. Maycox PR, DeckwerthT, Jahn R. 1990. Bacteriorhodopsin drives the glutamate transporter of synaptic vesicles after co-reconstitution. EMBO J. 9:1465-69
90. Merickel A, Edwards RH. 1995. Transport of histamine by vesicular monoamine transporter-2. Neuropharmacol. 34:1543-47
91. Merickel A, Rosandich P, Peter D, Edwards RH. 1995. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem. 270:25798-804
92. Michel PP, Hefti F. 1990. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26:428-35
93. Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. 1985. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61:195-200
94. Moriyama Y, Amakatsu K, Yamada H, Park M, Futai M. 1991. Inhibition of neurotransmitter and hormone transport into secretory vesicles by 2-4-phenylpiperidinocyclohexanol and 2-bromo-alpha-ergocryptine: Both compounds act as uncouplers and dissipate the electrochemical gradient of protons. Arch. Biochem. Biophys. 290:233-38
95. +) and the structurally related compounds in vitro and in vivo. Eur. Neurol. 26:11-15 (Suppl. 1)
96. Naito S, Ueda T. 1983. Adenosine trephosphate-dependent uptake of glutamate into protein 1-associated synaptic vesicles. J. Biol. Chem. 258:696-99
97. Nakanishi N, Onozawa S, Matsumoto R, Hasegawa H, Yamada S. 1995. Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic AMP-dependent down-regulation of vesicular monoamine transport in pheochromocytoma PC12 cells. FEBS Lett. 368:411-14
98. Neal RJ, Chater KF. 1987. Nucleotide sequence analysis reveals similarities between proteins determining methylenomycin A resistance in streptomyces and tetracycline resistance in eubacteria. Gene 58:229-41
99. Nelson N. 1992. Structure and function of V-ATPases in endocytic and secretory organelles. J. Exp. Biol. 172:149-53
100. Neyfakh AA, Bidnenko VE, Chen LB. 1991. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. USA 88:4781-85
101. Nguyen ML, Parsons SM. 1995. Effects of internal pH on the acetylcholine transporter of synaptic vesicles. J. Neurochem. 64:1137-42
102. Nguyen TT, Postle K, Bertrand KP. 1983. Sequence homology between the tetracycline-resistance determinants of Tn10 and pBR322. Gene 25:83-92
103. Nicklas WJ, Vyas I, Heikkila RE. 1985. Inhibition of NADH-linked oxidation in brain mitochondrai by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:2503-8
104. Nirenberg MJ, Liu Y, Peter D, Edwards RH, Pickel VM. 1995. The vesicular monoamine transporter-2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc. Natl. Acad. Sci. USA 92:8773-77
105. Niwa T, Takeda N, Kaneda N, Hashizume Y, Nagatsu T. 1987. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem. Biophys. Res. Commun. 144:1084-89
106. Okada Y, Yamazaki H, Sekine-Aizawa Y, Hirokawa N. 1995. The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. Cell 81:769-80
107. Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1364-71
108. Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:176-83
109. Parkinson Study Group. 1996. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39:29-36
110. Parsons SM, Prior C, Marshall IG. 1993. Acetylcholine transport, storage and release. Int. Rev. Neurobiol. 35:279-90
111. Peter D, Finn JP, Klisak I, Liu Y, Kojis T, et al. 1993. Chromosomal localization of the human vesicular amine transporter genes. Genomics 18:720-23
112. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH. 1994. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269:7231-37
113. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. 1995. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15:6179-88
114. Pifl C, Giros B, Caron MG. 1993. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13:4246-53
115. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, et al. 1992. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1658-67
116. Ramsay RR, Singer TP. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261:7585-87
117. Redhead CR, Edelman AE, Brown D, Landry DW, al-Awqati Q. 1992. A ubiquitous 64-kD protein is a component of a chloride channel of plasma and intracellular membranes. Proc. Natl. Acad. Sci. USA 89:3716-20
118. Riachi NJ, Behmand RA, Harik SI. 1991. Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood-brain barrier in vitro in five rat strains. Brain Res. 555:19-24
119. Riederer P, Sofic E, Rausch, W-D, Schmidt B, et al. 1989. Transition metals, ferritin, glutathione, and ascorbic acid Parkinson brains. J. Neurochem. 52:515-20
120. Roghani A, Feldman J, Kohan SA, Shirzadi A, Gundersen CB, et al. 1994. Molecular cloning of a putative vesicular transporter for acetylcholine. Proc. Natl. Acad. Sci. USA 91:10620-24
121. Rosenberg PA. 1988. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8:2887-94
122. 3H-vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. Neuroscience 35:327-33
123. Rudnick G, Steiner-Mordoch SS, Fishkes H, Stem-Bach Y, Schuldiner S. 1990. Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29:603-8
124. Rudnick G, Wall SC. 1992. The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamin (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 89:1817-21
125. Ryan TA, Reuter H, Wendland B, Schweizer FE, Tsien RW, Smith SJ. 1993. The kinetics of synaptic vesicle recycling measured at single presynaptic boutons. Neuron 11:713-24
126. Saporito MS, Heikkila RE, Youngster SK, Nicklas WJ, Geller HM. 1992. Dopaminergic neurotoxicity of the 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J. Pharmacol. Exp. Ther. 260:1400-9
127. Schapira A, Cooper J, Dexter D, Clark J, et al. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:823-7
128. Scherman D, Darchen F, Desnos C, Henry JP. 1988. 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine transport System of chromaffin granules. Eur. J. Pharmacol. 146:359-60
129. Scherman D, Henry JP. 1984. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25:113-22
130. Schuldiner S, Liu Y, Edwards RH. 1993. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J. Biol. Chem. 268:29-34
131. Schuldiner S, Shirvan A, Linial M. 1995. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75:369-92
132. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G. 1993b. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44:1227-31
133. Shimada S, Kitayama S, Walther D, Uh G. 1992. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Mol. Brain Res. 13:359-62
134. Shirvan A, Laskar O, Steiner-Mordoch S, Schuldiner S. 1994. Histidine-419 plays a role in energy coupling in the vesicular monoamine transporter from rat. FEBS Lett. 356:145-50
135. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. 1991. Mitochondrial oxidative phosphorylation in Parkinson's disease. Ann. Neurol. 30:332-39
136. Sofie E, Riederer P, Heinsen H, Beckmann H, et al. 1988. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neurol. Transm. 74:199-205
137. Steele TD, McCann UD, Ricaurte GA. 1994. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy): pharmacology and toxicology in animals and humans. Addiction 89:539-51
138. Stenstrom A, Sundstrom E, Fowler CJ. 1989. Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Pharmacol. Toxicol. 64:27281
139. Stern-Bach Y, Greenberg-Ofrath N, Flechner I, Schuldiner S. 1990. Identification and purification of a functional amine transporter from bovine chromaffin granules. J. Biol. Chem. 265:3961-66
140. Stern-Bach Y, Keen JN, Bejerano M, Steiner-Mordoch S, Wallach M, et al. 1992. Homology of a vesicular amine transporter to a gene conferring resistance to 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 89:9730-33
141. Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RAF. 1989. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J. Biol. Chem. 264:13572-78
142. Sulzer D, Maidment NT, Rayport S. 1993. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60:527-35
143. Sulzer D, Rayport S. 1990. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5:797-808
144. Surratt CK, Persico AM, Yang X-D, Edgar SR, Bird GS, et al. 1993. A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs. FEBS Lett. 318:325-30
145. Suzuki K, Mizuno Y, Yoshida M. 1988. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline. Neurosci. Lett. 86:105-8
146. Suzuki K, Mizuno Y, Yoshida M. 1990. Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain. Neurochem. Res. 15:705-10
147. Tabb JS, Kish PE, Van Dyke R, Ueda T. 1992. Glutamate transport into synaptic vesicles. J. Biol. Chem. 267:15412-18
148. Tanner CM, Langston JW. 1990. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40:17-30
149. + neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349:414-18
150. Varoqui H, Diebler M-F, Meunier F-M, Rand JB, Usdin TB, et al. 1994. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo. Homology with the putative vesicular acetylcholine transporter UNC-17 from Caenorhabditis elegans. FEBS Lett. 342:97-102
151. 3H]dihydrotetrabenazine-binding protein from bovine adrenal medulla. Mol. Pharmacol. 40:889-94
152. Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Came DB. 1994. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 36:765-70
153. Wall SC, Gu H, Rudnick G. 1995. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol. Pharmacol. 47:544-50
154. Walter P, Johnson AE. 1994. Signal sequence recognition and protein targeting to the endoplasmic reticulum membrane. Annu. Rev. Cell Biol. 10:87-119
155. Weaver JH, Deupree JD. 1982. Conditions required for reserpine binding to the catecholamine transporter on chromaffin granule ghosts. Eur. J. Pharmacol. 80:437-38
156. Westlund KN, Denney RM, Rose RM, Abell CW. 1988. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25:439-56
157. Yelin R, Schuldiner S. 1995. The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters. FEBS Lett. 377:201-7